Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma
Open Access
- 11 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 123 (2), 226-239
- https://doi.org/10.1038/s41416-020-0877-8
Abstract
Background Human urothelial carcinoma (UC) has a high tendency to recur and progress to life-threatening advanced diseases. Advanced therapeutic regimens are needed to control UC development and recurrence. Methods We pursued in vitro and in vivo studies to understand the ability of a triple combination of gemcitabine, romidepsin, and cisplatin (Gem+Rom+Cis) to modulate signalling pathways, cell death, drug resistance, and tumour development. Results Our studies verified the ability of Gem+Rom+Cis to synergistically induce apoptotic cell death and reduce drug resistance in various UC cells. The ERK pathway and reactive oxygen species (ROS) played essential roles in mediating Gem+Rom+Cis-induced caspase activation, DNA oxidation and damage, glutathione reduction, and unfolded protein response. Gem+Rom+Cis preferentially induced death and reduced drug resistance in oncogenic H-Ras-expressing UC vs. counterpart cells that was associated with transcriptomic profiles related to ROS, cell death, and drug resistance. Our studies also verified the efficacy and safety of the Gem plus Rom+Cis regimen in controlling UC cell-derived xenograft tumour development and resistance. Conclusions More than 80% of UCs are associated with aberrant Ras-ERK pathway. Thus the compensatory combination of Rom with Gem and Cis should be seriously considered as an advanced regimen for treating advanced UCs, especially Ras-ERK-activated UCs.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (CA177834)
This publication has 60 references indexed in Scilit:
- Romidepsin: a novel histone deacetylase inhibitor for cancerExpert Opinion on Investigational Drugs, 2011
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011
- Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cellsZeitschrift für Krebsforschung und Klinische Onkologie, 2010
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJournal of Hematology & Oncology, 2010
- The Tumor Suppressor Par-4 Activates an Extrinsic Pathway for ApoptosisCell, 2009
- Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase inductionZeitschrift für Krebsforschung und Klinische Onkologie, 2009
- Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cellsZeitschrift für Krebsforschung und Klinische Onkologie, 2007
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatoninOncogene, 2003
- Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformationOncogene, 1999